To evaluate the diagnostic efficacy of plasma ctDNA and comparisons with tumor biomarkers: CA19-9 and CEA, 62 plasma CCA samples were tested for one or more of the biomarkers. This evidence concerns the gene CEACAM5 and neoplasm.